Here is a brief article on a subject that we know all too well. It seems to be virtually impossible to escape the “post cancer fear” phenomenon, no matter how well you may be feeling. It may be even more difficult for those of us who continue to experience the late effects of treatments. As the wonderful Roseanne Roseannadanna used to say, “It’s always something!” Owning those fears, as it turns out, could be part of turning the corner.
By Matt Ellis and Regina Norfolk – January 2024 marked 25 years that Elena Togashi has been in remission from Hodgkin lymphoma. To mark this incredible milestone, the 45-year-old cancer survivor will run this year’s Boston Marathon with the Dana-Farber Marathon Challenge team.
The Leukemia and Lymphoma Society offers numerous programs and webinars via their website and “The Bloodline With LLS.” This webinar is a great example of how LLS continues to support survivors of all ages. Monica Bryant, cancer rights attorney and founder of “Triage Cancer” provides spot-on advice as well as several resources on the subject of financial toxicity.
A new first-line chemotherapy regimen of prednisone, vinblastine, doxorubicin, and bendamustine (PVAB) yields a high complete metabolic response (CMR) rate with acceptable toxicity in older patients with classical Hodgkin lymphoma (cHL), according to research published in Blood.
This article describes research done by the Childhood Cancer Survivor Study of St. Jude Children’s Research Hospital and CARDIA, which stands for “Coronary Artery Risk Development in Young Adults.” These two organizations combined their data bases to create an in-depth study of the specific risks for childhood cancer survivors. The results are concerning, and they underline the need for early and frequent observation post treatment.
Hodgkin’s International was honored to be mentioned in this recent article about late effects that appeared in “Cancer Today,” a publication of the American Association for Cancer Research.
VivorCare is the first virtual survivorship clinic for those living with and beyond cancer.
Meet Dr. Stephanie Smith, Dr. Lidia Schapira, Elle Billman, and Dr. Natasha Steele – the “dream team” from Stanford Medicine who have created an exciting new resource for cancer survivors. This podcast offers a unique opportunity to hear directly from both survivors and experts in survivorship care on a wide range of subjects. It is informative, engaging, and just what we need to feel less alone in our struggles.
This article in HemOnc Today describes a recent study that evaluated the use of specific biomarkers, namely global longitudinal strain (GLS) and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) to identify childhood cancer survivors who may be at risk for cardiomyopathy. The study was done through the St. Jude Lifetime Cohort study.